GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on November 10, 2022, by GSK Plc, serves as a transaction notification for the month of November 2022. The filing discloses share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific equity transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| November 9, 2022 | Ordinary Shares (31 1/2 pence each) | £13.9638 | 16 to 18 shares per individual | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine compliance disclosures regarding insider share acquisitions.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of share transactions.
Key Facts for Investor Verification
- Transaction Type: All reported transactions were acquisitions of Ordinary Shares under the Company's Share Reward Plan.
- Participants: Transactions involved senior executives including the CEO (Ms E Walmsley), President of Vaccines (Mr R Connor), and other senior leadership.
- Volume: Individual transaction volumes were minimal, ranging from 16 to 18 shares per person.
- Pricing: All shares were acquired at a uniform price of £13.9638.
- Scope: This filing does not contain financial performance data; investors should refer to Form 20-F or quarterly reports for financial metrics.